The structural requirements for multisite AChE inhibitorsimposedby the AChE gorge shape a particular type of molecule that can inherentlymodulate other key targets in AD, such as BACE-1 and β-amyloid(Aβ) and tau aggregation. The gene discussed is BACE1; the disease is Alzheimer disease.